{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:04Z","timestamp":1791896344550,"version":"4.3.4"},"reference-count":30,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Patients with stage IIIA cutaneous melanoma have relatively favorable prognoses (5-and 10-year overall survival probabilities of 93% and 88%, respectively), yet they are considered for systemic adjuvant therapy. Identifying the subset of patients at highest risk of recurrence could limit adjuvant treatment\u2013related toxicity and direct therapy to those most likely to benefit.\n                    <jats:bold>Patients and Methods:<\/jats:bold>\n                    Patients aged \u226518 years with stage IIIA melanoma diagnosed between 2001 and 2016 at 36 centers, primarily in Europe and North America, were included in the study. The full cohort was split in a 3:1 ratio into development (n=1,386) and validation (n=448) cohorts. A random forest procedure was applied to the development cohort to select variables for inclusion. The selected variables were incorporated into a Fine\u2013Gray model to predict recurrence-free survival and graphically represented as a nomogram. Model performance was assessed using the C-index and inspection of the calibration plot. The model\u2019s clinical utility was assessed using decision curve analysis and compared with alternative strategies.\n                    <jats:bold>Results:<\/jats:bold>\n                    Eight variables were included in the model and were associated with the incidence of recurrence: mitotic rate (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), number of positive sentinel lymph nodes (SLNs) per nodal basin (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), diameter of the largest focus in the SLN (\n                    <jats:italic>P<\/jats:italic>\n                    =.001), ulceration (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), age (\n                    <jats:italic>P<\/jats:italic>\n                    =.022), number of metastatic foci in the SLN (\n                    <jats:italic>P<\/jats:italic>\n                    =.019), lymphovascular invasion (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), and extranodal extension (\n                    <jats:italic>P<\/jats:italic>\n                    =.005). In the validation cohort, the model had a C-index of 80.9% and appeared to be well calibrated. Decision curve analysis demonstrated a significant net benefit for adjuvant therapy guided by the nomogram compared with alternative strategies, including treating all patients with adjuvant therapy, treating no patients, or treating only patients with stage IIIA disease and &gt;1.0-mm nodal tumor burden.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our prediction model can improve patient selection for adjuvant therapy compared with other available strategies.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2026.7049","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:39Z","timestamp":1791895239000},"source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of a Model to Predict Recurrence in Patients With Stage IIIA Melanoma"],"prefix":"10.6004","volume":"24","author":[{"given":"Andrea","family":"Maurichi","sequence":"first","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barretta","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea P.","family":"Moy","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Patuzzo","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Taglione","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Podlidnik","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Wright","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Walker","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Look Hong","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[{"name":"University of Padua, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Dell\u2019Olmo","sequence":"additional","affiliation":[{"name":"University of Padua, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveria","family":"Tropea","sequence":"additional","affiliation":[{"name":"University of Padua, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Borgognoni","sequence":"additional","affiliation":[{"name":"Santa Maria Annunziata Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Sestini","sequence":"additional","affiliation":[{"name":"Santa Maria Annunziata Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Gerlini","sequence":"additional","affiliation":[{"name":"Santa Maria Annunziata Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Picciotto","sequence":"additional","affiliation":[{"name":"University Hospital of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"University Hospital of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"University Hospital of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Benedetto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sparano","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[{"name":"University Hospital of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peri\u0107","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana, Slovenia, and Faculty of Medicine, University Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mili\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana, Slovenia, and Faculty of Medicine, University Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Roshan","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer J.","family":"Durrani","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Egger","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"McMasters","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nagore","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Oncologia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Manrique-Silva","sequence":"additional","affiliation":[{"name":"Instituto Valenciano de Oncologia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Nessin","sequence":"additional","affiliation":[{"name":"University Hospital of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Boada","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e8 L.","family":"Manzano Mozo","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pi\u00f1ero-Madrona","sequence":"additional","affiliation":[{"name":"University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigaci\u00f3n, Biosanitaria (IMIB), Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Cerezuela-Fuentes","sequence":"additional","affiliation":[{"name":"University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigaci\u00f3n, Biosanitaria (IMIB), Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Karakousis","sequence":"additional","affiliation":[{"name":"University Hospital of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cimarron","family":"Sharon","sequence":"additional","affiliation":[{"name":"University Hospital of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[{"name":"Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Shimonovitz-Moore","sequence":"additional","affiliation":[{"name":"Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Longo","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia, Modena, Italy"},{"name":"University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[{"name":"University of Campania, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odysseas","family":"Zoras","sequence":"additional","affiliation":[{"name":"University Keele Greece, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostantinos","family":"Lasithiotakis","sequence":"additional","affiliation":[{"name":"University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale dei Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Paradela de la Morena","sequence":"additional","affiliation":[{"name":"University Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ca\u00f1ueto","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rodr\u00edguez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de la Princesa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jim\u00e9nez Gallo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta del Mar, Cadiz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzan","family":"Solimani","sequence":"additional","affiliation":[{"name":"Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mangas","sequence":"additional","affiliation":[{"name":"Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Espeli","sequence":"additional","affiliation":[{"name":"Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ba\u00f1uls","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante, ISABIAL, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Samaniego-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Le\u00f3n, Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Mu\u00f1oz","family":"Couselo","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca J.","family":"de Unamuno-Bustos","sequence":"additional","affiliation":[{"name":"La Fe University Hospital, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[{"name":"IRCCS Ospedale Sacro Cuore-Don Calabria, Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tejera-Vaquerizo","sequence":"additional","affiliation":[{"name":"Hospital San Juan de Dios de C\u00f3rdoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Skagit Regional Health, Mount Vernon, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Santinami","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"New Engl J Med","first-page":"1307","article-title":"Sentinel node biopsy or nodal observation in melanoma","volume":"355","author":"Morton DL","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ,  Sentinel node biopsy or nodal observation in melanoma. New Engl J Med 2006;355:1307\u20131317."},{"key":"B2","series-title":"AJCC Cancer Staging Manual.","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald JE","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR,  Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, , eds. AJCC Cancer Staging Manual. Springer; 2017:563\u2013585."},{"key":"B3","series-title":"Lancet Oncol","first-page":"1465","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto PA","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M,  Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:1465\u20131477."},{"key":"B4","series-title":"Lancet Oncol","first-page":"358","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer R","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J,  Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol 2020;21:358\u2013372."},{"key":"B5","series-title":"Eur J Cancer","first-page":"114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial","volume":"211","author":"Eggermont AM","year":"2024","unstructured":"Eggermont AM, Kicinski M, Blank CU,  Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325\/KEYNOTE-054 trial. Eur J Cancer 2024;211:114327."},{"key":"B6","series-title":"J Immunother Cancer","first-page":"e004272","article-title":"Association of selected (immune- related) adverse events and outcome in two adjuvant phase III trials, CheckMate-238 and EORTC1325\/KEYNOTE-054","volume":"10","author":"Eggermont A","year":"2022","unstructured":"Eggermont A, Kicinski M, Suciu S. Association of selected (immune- related) adverse events and outcome in two adjuvant phase III trials, CheckMate-238 and EORTC1325\/KEYNOTE-054. J Immunother Cancer 2022;10:e004272."},{"key":"B7","series-title":"Ann Oncol","first-page":"807","article-title":"Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma","volume":"36","author":"Grover P","year":"2025","unstructured":"Grover P, Lo SN, Li I,  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Ann Oncol 2025;36:807\u2013818."},{"key":"B8","series-title":"J Clin Oncol","first-page":"4794","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth R","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H,  Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol 2023;41:4794\u20134820."},{"key":"B9","series-title":"Ann Oncol","first-page":"1449","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO guidelines committee","volume":"31","author":"Michielin O","year":"2020","unstructured":"Michielin O, van Akkooi A, Lorigan P,  ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO guidelines committee. Ann Oncol 2020;31:1449\u20131461."},{"key":"B10","article-title":"NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 3.2024","author":"Swetter SM","unstructured":"Swetter SM, Johnson D, Albertini MR,  NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 3.2024. Accessed June 1, 2026. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B11","series-title":"Ann Surg Oncol","first-page":"5329","article-title":"Impact of adjuvant immunotherapy on overall survival in a contemporary cohort of patients with stage III melanoma","volume":"30","author":"Sharon CE","year":"2023","unstructured":"Sharon CE, Tortorello GN, Ma K,  Impact of adjuvant immunotherapy on overall survival in a contemporary cohort of patients with stage III melanoma. Ann Surg Oncol 2023;30:5329\u20135332."},{"key":"B12","series-title":"J Clin Oncol","first-page":"3345","article-title":"The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement","volume":"22","author":"Dewar DJ","year":"2004","unstructured":"Dewar DJ, Newell B, Green MA,  The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004;22:3345\u20133349."},{"key":"B13","series-title":"Ann Surg","first-page":"949","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi ACJ","year":"2008","unstructured":"van Akkooi ACJ, Nowecki ZI, Voit C,  Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008;248:949\u2013955."},{"key":"B14","series-title":"Control Clin Trials","first-page":"343","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper M","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343\u2013346."},{"key":"B15","series-title":"J Amer Stat Assoc","first-page":"1198","article-title":"A test of missing completely at random for multivariate data with missing values","volume":"83","author":"Little RJA","year":"1988","unstructured":"Little RJA. A test of missing completely at random for multivariate data with missing values. J Amer Stat Assoc 1988;83:1198\u20131202."},{"key":"B16","series-title":"Mach Learn","first-page":"5","article-title":"Random forests","volume":"45","author":"Breiman L","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn 2001;45:5\u201332."},{"key":"B17","series-title":"Bioinformatics","first-page":"1340","article-title":"Permutation importance: a corrected feature importance measure","volume":"26","author":"Altmann A","year":"2010","unstructured":"Altmann A, Tolo\u015fi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance measure. Bioinformatics 2010;26:1340\u20131347."},{"key":"B18","series-title":"Stat Med","first-page":"5381","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche P","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 2013;32:5381\u20135397."},{"key":"B19","series-title":"Stat Med","first-page":"361","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell FEJ","year":"1996","unstructured":"Harrell FEJ, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361\u2013387."},{"key":"B20","series-title":"Lancet Digit Health","first-page":"100916.","article-title":"Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance","volume":"7","author":"Van Calster B","year":"2025","unstructured":"Van Calster B, Collins GS, Vickers AJ,  Evaluation of performance measures in predictive artificial intelligence models to support medical decisions: overview and guidance. Lancet Digit Health 2025;7:100916."},{"key":"B21","series-title":"Semin Oncol","first-page":"31","article-title":"Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework","volume":"37","author":"Vickers AJ","year":"2010","unstructured":"Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework. Semin Oncol 2010;37:31\u201338."},{"key":"B22","series-title":"N Engl J Med","first-page":"1709","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long GV","year":"2024","unstructured":"Long GV, Hauschild A, Santinami M,  Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2024;391:1709\u20131720."},{"key":"B23","series-title":"J Clin Oncol","first-page":"6199","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch CM","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ,  Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199\u20136206."},{"key":"B24","series-title":"J Clin Oncol","first-page":"1619","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke JJ","year":"2024","unstructured":"Luke JJ, Ascierto PA, Khattak MA,  Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol 2024;42:1619\u20131624."},{"key":"B25","series-title":"Front Oncol","first-page":"1336441","article-title":"Immunotherapy utilization in stage IIIA melanoma: less may be more","volume":"14","author":"Frey AE","year":"2024","unstructured":"Frey AE, Kerekes DM, Khan SA,  Immunotherapy utilization in stage IIIA melanoma: less may be more. Front Oncol 2024;14:1336441."},{"key":"B26","series-title":"J Clin Oncol","first-page":"3940","article-title":"Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer IIIA disease","volume":"40","author":"Moncrieff MD","year":"2022","unstructured":"Moncrieff MD, Lo SN, Scolyer RA,  Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer IIIA disease. J Clin Oncol 2022;40:3940\u20133951."},{"key":"B27","series-title":"Lancet Oncol","first-page":"509","article-title":"Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis","volume":"25","author":"Stassen RC","year":"2024","unstructured":"Stassen RC, Maas CCHM, van der Veldt AAM,  Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol 2024;25:509\u2013517."},{"key":"B28","series-title":"Ann Surg Oncol","first-page":"5948","article-title":"Clinically significant risk thresholds in the management of primary cutaneous melanoma: a survey of melanoma experts","volume":"29","author":"Bartlett EK","year":"2022","unstructured":"Bartlett EK, Grossman D, Swetter SM,  Clinically significant risk thresholds in the management of primary cutaneous melanoma: a survey of melanoma experts. Ann Surg Oncol 2022;29:5948\u20135956."},{"key":"B29","series-title":"BMC Cancer","first-page":"130","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager JS","year":"2018","unstructured":"Zager JS, Gastman BR, Leachman S,  Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 2018;18:130."},{"key":"B30","series-title":"Ann Surg Oncol","first-page":"1429","article-title":"Society of Surgical Oncology Consensus Statement: assessing the evidence for and utility of gene expression profiling of primary cutaneous melanoma","volume":"32","author":"Bartlett EK","year":"2025","unstructured":"Bartlett EK, O\u2019Donoghue C, Boland G,  Society of Surgical Oncology Consensus Statement: assessing the evidence for and utility of gene expression profiling of primary cutaneous melanoma. Ann Surg Oncol 2025;32:1429\u20131442."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e267049.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e267049.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e267049.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:39Z","timestamp":1791895239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e267049.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7049","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}